Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
The results obtained in this study suggest that Akti-1/2 might be a better inhibitor for the treatment of BC caused by the E17K mutation in AKT1.
|
31698236 |
2019 |
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
AKT1 mutations (E17K) have been found in 1.4-8% of breast cancer patients.
|
29086897 |
2018 |
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
Analysis of TCGA breast cancer data revealed that the mRNA expression, total protein levels, and phosphorylation of various RTKs are decreased in human tumors harboring AKT1(E17K).
|
27004402 |
2016 |
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
The data suggest that AKT1 (E17K) is the most likely disease driver in certain breast cancer patients.
|
27515171 |
2016 |
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
Both AKT inhibitors caused highly significant growth inhibition of breast cancer explant models with AKT1(E17K) mutation.
|
26351323 |
2015 |
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
AKT1 E17K is a bona fide oncogene in a human luminal breast cancer context.
|
23888070 |
2013 |
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
This study demonstrated that the AKT1 E17K mutation occurs in breast cancers at a low frequency, and that it is rare in other common cancers, including colorectal, lung, gastric and hepatocellular carcinomas and acute leukaemias.
|
18392055 |
2008 |
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
UNIPROT |
|
|
|
Proteus Syndrome
|
|
0.730 |
GeneticVariation
|
BEFREE |
Proteus syndrome (PS) is an ultra-rare disease characterized by progressive, disproportionate, segmental overgrowth caused by a somatic gain-of-function mutation p.Glu17Lys in the oncogene AKT1.
|
31058421 |
2019 |
Proteus Syndrome
|
|
0.730 |
GeneticVariation
|
BEFREE |
A somatic activating mutation in AKT1, c.49G>A, pGlu17Lys, that results in elevated AKT signaling in mutation-positive cells, is responsible for the mosaic overgrowth condition, Proteus syndrome.
|
26657992 |
2015 |
Proteus Syndrome
|
|
0.730 |
GeneticVariation
|
BEFREE |
Of 29 patients with the Proteus syndrome, 26 had a somatic activating mutation (c.49G→A, p.Glu17Lys) in the oncogene AKT1, encoding the AKT1 kinase, an enzyme known to mediate processes such as cell proliferation and apoptosis.
|
21793738 |
2011 |
Proteus Syndrome
|
|
0.730 |
GeneticVariation
|
UNIPROT |
Of 29 patients with the Proteus syndrome, 26 had a somatic activating mutation (c.49G→A, p.Glu17Lys) in the oncogene AKT1, encoding the AKT1 kinase, an enzyme known to mediate processes such as cell proliferation and apoptosis.
|
21793738 |
2011 |
Proteus Syndrome
|
|
0.730 |
GeneticVariation
|
UNIPROT |
Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain.
|
18954143 |
2008 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two mutations were identified in the tumor tissue by NGS and sanger sequencing: AKT1 E17K and BRAF (B-Raf proto-oncogene, serine/threonine kinase) V600E.
|
31546071 |
2019 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The whole exome sequencing showed that AKT1 E17K mutation was high (26.316%) in tumor tissue, and dynamic monitoring of circulating tumor DNA indicated that AKT1 E17K mutation rate was increasing successively and highly consistent with tumor growth in peripheral blood.
|
31802899 |
2019 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Results In patients with AKT1 E17K-mutant tumors (n = 52) and a median of five lines of prior therapy, the median PFS was 5.5 months (95% CI, 2.9 to 6.9 months), 6.6 months (95% CI, 1.5 to 8.3 months), and 4.2 months (95% CI, 2.1 to 12.8 months) in patients with estrogen receptor-positive breast, gynecologic, and other solid tumors, respectively.
|
28489509 |
2017 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
To enable prospective screening for the low prevalence AKT1 E17K mutation, we have developed and validated a competitive allele-specific TaqMan® PCR (castPCR™) assay for mutation detection in formalin-fixed paraffin-embedded (FFPE) tumor tissue.
|
28472036 |
2017 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although AKT1-mutant tumor specimens were often found to harbor concurrent alterations in other driver genes, a subset of specimens harboring AKT1 (E17K) as the only known driver alteration was also identified.
|
27515171 |
2016 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Compound 21a also served as a potent inhibitor of the AKT1-E17K mutant protein and inhibited tumor growth in a human xenograft mouse model of endometrial adenocarcinoma.
|
27305487 |
2016 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The results showed that activating mutations in either PIK3CA or AKT1 were identified in 20 tumors (67%); 19 tumors had PIK3CA mutations (63%; 13 in exon 20 and 6 in exon 9), and 1 had an AKT1 E17K mutation (3%).
|
27184479 |
2016 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The data show that tumors with AKT1(E17K) mutations are rational therapeutic targets for AKT inhibitors, although combinations with other targeted agents may be required where activating oncogenic mutations of other proteins are present in the same tumor.
|
26351323 |
2015 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The AKT1 (E17K) mutation in the tumor was not detectable in all investigated specimens.
|
26077595 |
2015 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we report that in immortalized human bronchial epithelial cells (BEAS-2B cells) mutant AKT1-E17K promotes anchorage-dependent and -independent proliferation, increases the ability to migrate, invade as well as to survive and duplicate in stressful conditions, leading to the emergency of cells endowed with the capability to form aggressive tumours at high efficiency.
|
26053093 |
2015 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Knockin of the AKT1 E17K hotspot mutation on this PIK3CA wild-type background restored pathway signaling, proliferation, and tumor growth in vivo.
|
23888070 |
2013 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The AKT1 (E17K) mutation has been reported in some tumour types (breast, colorectal, ovarian and lung cancers), and it is of interest which tumour types other than those possess the E17K mutation.
|
19491896 |
2009 |